
    
      This is a open-label study of single doses of intravenous BNZ132-1-40 administered to healthy
      adult subjects. Subjects are followed for 30 days after treatment for collection of safety,
      PK and PD data. Cohorts of up to 6 subjects will be enrolled for each dose level.
    
  